UBT251

UBT251

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

An investigational GLP-1/GIP/glucagon triple-agonist peptide with published randomized Phase 1a/1b and 24-week Phase 2 weight-management research.

Plain English

UBT251 is being studied for weight management. Early trials and a published 24-week Phase 2 trial reported weight reductions and gastrointestinal adverse events, generally mild to moderate in Phase 2. These findings cannot predict an individual's benefit, and longer-term efficacy and safety remain uncertain.

Overview

UBT251 is an investigational peptide agonist of GLP-1, GIP and glucagon receptors. A randomized, double-blind, placebo-controlled Phase 1a/1b publication studied subcutaneous administration, with safety and tolerability as primary endpoints. A published multicenter, randomized, double-blind, placebo-controlled Phase 2 trial studied 205 adults with overweight or obesity without type 2 diabetes for 24 weeks. These studies do not establish an approved obesity treatment or long-term efficacy and safety.

Research Summary

The Phase 1a study evaluated single ascending subcutaneous doses; the Phase 1b study evaluated 12 weeks of once-weekly treatment in participants with overweight or obesity without diabetes. In the reported active-dose groups, mean weight reductions ranged from 8.96 to 13.48 kg, compared with a 1.57 kg increase with placebo. Laboratory investigations, decreased appetite and gastrointestinal adverse events were the most commonly reported adverse effects. Approximately linear pharmacokinetics were reported within the studied 1.0–6.0 mg range; this is study-specific, not a dosing recommendation. A subsequent published multicenter, randomized, double-blind, placebo-controlled Phase 2 trial studied 205 adults with overweight or obesity without type 2 diabetes for 24 weeks. At week 24, least-squares mean body-weight reductions ranged from 13.6% to 19.7% across UBT251 groups, compared with 2.0% with placebo. Gastrointestinal adverse events were commonly reported and generally mild to moderate. Longer-term efficacy and safety remain uncertain; these trial findings do not establish individual outcomes or an approved treatment.

Research Areas

  • Obesity research
  • Weight management
  • GLP-1/GIP/glucagon receptor research

Safety & Risks

Reported Side Effects

  • Gastrointestinal adverse events
  • Decreased appetite
United States
Investigational research; no approved clinical use is asserted by this record.
United Kingdom
Current authorization status not established in this record.
Australia
Current authorization status not established in this record.
Canada
Current authorization status not established in this record.

Citations & Sources